The neuropeptide arginine vasopressin (AVP) can replace the cytokine interleukin 2 (IL-2) as a T-cell mitogen for the induction of interferon y (IFN y) expression in splenic cultures. IL-2-like and IL-2 receptor immunoreactivity have been reported in different brain regions, under normal and pathophysiological conditions. Regulatory functions for IL-2 in the CNS have been suggested.
In addition to the spleen, AVP might also mediate some IL-2 effects centrally. In the present study, we evaluated the effect of IL-2 on the in vitro release of AVP from the hypothalamus and amygdala.
In addition, we used these release systems to study the possible involvement of NO-mediated signaling in AVP release, based on the reported detection of nitric oxide synthase (NOS) in the hypothalamus and amygdala. IL-2 rapidly stimulates AVP release in both regions, in a calcium-and dose-dependent manner. In addition, nitroprusside also induces AVP release. Norepinephrine also induces AVP release from both the hypothalamus, as well as the amygdala. The norepinephrineinduced AVP release is antagonized by phentolamine, but not by propanolol, suggesting an a-adrenergic receptor-mediated AVP response in both brain regions. The IL-2-and acetylcholine-induced AVP release is antagonized by Nomethyl-L-arginine, indicating a role for NO in this AVP release. N-methyl-L-arginine does not affect the norepinephrine-induced AVP release. A stimulatory effect of IL-2 on hypothalamic CRF release and plasma ACTH has already been reported.
(IL-1) and IL-2 appear to be essential for the immune response (Claman, 1987) . IL-l/3 has been shown to stimulate the hypothalamo-pituitary-adrenal (HPA) axis, and its stimulation of adrenocorticotropin (ACTH) release has been ascribed both to an increased release of corticotropin-releasing factor (CRF) (Berkenbosch et al., 1987 (Berkenbosch et al., , 1989 Sapolsky et al., 1987; Saphier and Ovadia, 1990; Spinedi et al., 1992) and more recently to an increased release of arginine vasopressin (AVP) (Watanobe and Takebe, 1993; Raber et al., 1994) .
IL-2 is mainly synthesized by antigen-or mitogen-activated T-lymphocytes and enhances their proliferation after antigenic stimulation; IL-2 is also involved in controlling B-cell proliferation and their differentiation into antibody-secreting cells, and induces growth and activation of antigen-independent natural killer and lymphokine-activated killer cells (Nistico and De Sarro, 199 1) . Endogenous AVP in the CNS has been proposed to be involved in primary antibody responses (Croiset et al., 1990) , and AVP can replace the IL-2 requirement for T-cell mitogen induction of interferon y in mouse spleen cell cultures (Johnson and Torres, 1985) .
IL-2-like and IL-2 receptor immunoreactivity has been reported in different brain regions, under normal and pathophysiological conditions (Nieto-Sampredo and Chandy, 1987; Luber-Narod and Rogers, 1988; Lapchak and Araujo, 1993) , with the highest densities in the median eminence-arcuate nucleus complex of rats (Araujo et al., 1989; Lapchak et al., 199 1) and mice (Villemain et al., 1990) . IL-2 disruption and penetration of the blood-brain barrier has been reported (Ellison et al., 1987; Saris et al., 1988) , and the IL-2 in the CNS could originate from the brain or the periphery. In addition, it is not yet clear whether IL-2 is released from neurons, astrocytes, or microglia. The release of IL-2 from brain slices is not increased in the presence of high potassium, which suggests that IL-2 is not released from nerve terminals by voltage-sensitive mechanisms (Araujo et al., 1989) .
Elevated IL-2 levels have been detected in the CSF of neuroleptic-free schizophrenic patients (Licinio et al., 1993) and patients undergoing IL-2 immunotherapy (Saris et al., 1988) . Regulatory functions for IL-2 in the CNS have been suggested (Benveniste et al., 1987; Sabath et al., 1990; Nistico and De Sarro, 1991; Cohen et al., 1992; Sessa et al., 1992; Shimojo et al., 1993) . IL-2 induced an increase in plasma ACTH and cortisol levels (Bindon et al., 1983; Lotze et al., 1985; Atkins et al., 1986; Denicoff et al., 1989) . In addition, when IL-2 was microinjected into the third cerebral ventricle of rats, it significantly increased the neuronal discharge frequency in the supraoptic and paraventricular nuclei, which secrete AVP. This effect might explain the considerable water retention observed during IL-2 therapy (Bindoni et al., 1988) , which can lead to Raber and Bloom -IL- (Rosenberg and Lotze, 1986; Urba et al., 1990) . In addition, a single injection of IL-2 significantly increased hypothalamic AVP mRNA in nude mice after 12 hr, which remained elevated for 5 d (Pardy et al., 1993) . These effects would be explained if IL-2 could enhance AVP release. NO in the brain is considered a neuronal messenger and might be synthesized either presynaptically or postsynaptically, and may serve as a retrograde messenger (for review, see Garthwaite, 1991; Madison, 1993) . NO-mediated signaling might be involved in AVP release. NOS protein, NADPH-diaphorase activity, and mRNA have been detected in the supraoptic nucleus (Bredt and Snyder, 1992) . Furthermore, in dehydrated animals, which show elevated levels of AVP release (Jones and Pickering, 1969) , there is a strong increase in NOS immunoreactivity in all magnocellular neurons in the SON, including the ventral and caudal part (Pow, 1992) which contain mainly AVP neurons (Swaab et al., 1975) . In addition, colocalization of NOS and AVP has recently been reported in a subpopulation of AVP magnocellular neurons (Moffett and Paden, 1993) . NOS was also detected in the amygdala (Pow, 1992) which could be involved in the reported calcium-dependent AVP release from the amygdala (Raber et al., 1994) .
The objective of the present study is to determine whether IL-2 can affect the release of AVP from either the hypothalamus or amygdala, using in vitro paradigms of AVP release, and whether NO could regulate the release of AVP by IL-2 or neurotransmitters, such as acetylcholine and norepinephrine.
Materials and Methods
Animals. Male Sprague-Dawley rats (Charles River), weighing 200-250 gm, were used in all experiments. The rats were kept two per cage and housed under conditions of constant temperature (18"C), with lighting during 0600-l 800 hr, with access to water and food ad libitum.
Dissection of hypothalami and amygdala. Animals were sacrificed by decapitation between 1000 and 1100 hr to avoid circadian variation, and their brains rapidly removed. A brain slicer (San Diego Instruments) was used to obtain a 3-mm-thick coronal slice, including structures -1.8 mm caudal to bregma, according to Paxinos and Watson (1986) . The slice was then placed under a low-magnification microscope, and hypothalamic and amygdaloid regions were dissected out. Next the hypothalamus was defined as the region between two vertical cuts, starting from the two lateral hypothalamic sulci, and a horizontal cut through the mammillothalamic tracts and the rhomboid thalamic nucleus. The dissection of the amygdala was obtained by a vertical cut tangential to the external capsule and a diagonal cut along the medial border of the ipsilateral optic tract (Raber et al., 1994) . The dissected tissues were placed on a Brinkmann tissue chopper, and 300 pm slices were prepared.
Incubation system. Experiments were designed to measure the release of AVP from the sliced tissue. For this purpose, the slices were incubated in balanced Earle's salt solution (GIBCO), supplemented with 0.1% bovine albumin (Pentex), 60 &ml ascorbic acid (Fischer), 0.54 mg/ml glucose, 20 mM bacitracin (Sigma), 1 PM PMSF (Sigma), and 200 Kallikrein inhibitor units (KIU)/ml aprotinin (Boehringer-Mannheim) at 37°C under an atmosphere of O,/CO, (95%/5%), for a total of 160 min. The experimental design consisted of serial passage of the minced tissue through different wells [one hypothalamic or two amygdala explant(s) per well], which contained 700 ~1 of medium, at 20 min intervals, according to the method of Calogero et al. (1989) . Overnight, the 48-well plates (Costar) were precoated with "SPEA" buffer (10 mM NaH,PO,, 40 mM Na,PO,. 100 mM NaCl. 25 mM EDTA. 0.1% NaN,. DH 7.4).
-_, _I _ II containing 1% bovine albumin at 4°C. Media from the incubations were put on dry ice and stored at -70°C until assay for AVP immunoreactivity. The slices were preincubated for 80 min, after which basal AVP release is stabilized (Raber et al., 1994) . Between 80 and 100 min, a baseline sample was collected. The slices were exposed to a depolarizing concentration of KC1 (60 mM) for 20 min for testing of tissue viability at the end of the experiment. Data from experiments in which there was not a vigorous release (at least 50% over baseline) with 60 mM KC1 were discarded. For studying the effect of IL-2 on the AVP release from the hypothalamus (n = 7-11) and amygdala (n = 5-14) tissues were incubated with IL-2 (1.10.50. or 100 U/ml) between 100 and 120 min.
To investigate if AVP might be released'via NO, tissues were incubated with nitroprusside (100 PM) between 100 and 120 min (n = 8, hypothalamus; n = 20, amygdala). For studying the calcium dependency of the IL-2-induced AVP release, tissues were incubated with the calcium channel blocker CoCl, (10 mM) during basal and IL-2 stimulation (between 100 and 140 min; n = 7-28). To investigate the possibility that IL-2 might release AVP via NO, the IL-2 (100 U/ml)-induced AVP release was assessed in the presence of N*-methyl+arginine (LNMA; 10 PM), a competitive inhibitor of NOS. The inhibitor was present during the basal and IL-2-induced stimulation (between 80 and 120 min).
To determine whether acetylcholine or norepinephrine might also induce AVP release via NO. the Dharmacoloaicallv induced AVP release was assessed in the presence of ihe NOS inh:bitor LNMA (10 FM). The inhibitor was present during the basal and acetylcholine (1 PM; n = 7-13) or norepinephrine (1 PM; n = 9-l 7)-induced AVP release. In order to assure that any inhibition of the acetylcholine-induced AVP release by LNMA is specific, the acetylcholine-induced AVP release was also assessed in the presence of N*-methyl-D-arginine (DNMA), its inactive analog (n = 7-l 3). To investigate which adrenergic receptor is involved in the norepinephrine-induced release of AVP ( 1 PM), release was studied in the presence of propanolol (10 PM) or phentolamine (10 PM). The adrenergic antagonists were present during the basal and norepinephtine-induced stimulation (between 80 and 120 min; n = 8-2 1).
A VP RZA. The concentration of AVP in the media was measured in polypropylene tubes (Labcraft) by RIA according to the Skowsky method (Skowsky et al., 1974) , modified by Weitzman et al. (1978) , using a specific rabbit polyclonal antibody (gift from Dr. A. Burlet, Bordeaux, France) and synthetic vasopressin (gift from Dr. P. Plotsky, Atlanta, GA). Y-AVP was obtained from Amersham. Pretitered aoat anti-rabbit and normal rabbit sera were from Peninsula Laborat&ies, Inc. All standards were measured in triplicate and the medium samples were measured in duplicate. The lower detection limit of the assay was 3 pg/ tube (100 ~1 sample volume). The intra-and interassay coefficients of variation were 3% and lo%, respectively.
Substances. Human recombinant IL-2 was from Boehringer-Mannheim. Acetylcholine, norepinephrine, propanolol, phentolamine, cobalt chloride, nitroprusside, Ne-methyl+arginine, and M-methyl-o-arginine were from Sigma. All solutions were prepared immediately before incubation.
Statistics. Data, expressed as mean * SEM, were analyzed statistically using analysis of variance (ANOVA) followed by a Tukey test when appropriate. A probability value of less than 0.05 was considered significant.
Results
Efect of IL-2 on the basal AVP release from the hypothalamus and the amygdala As shown in Figure 1 , A and B, a 20 min IL-2 incubation stimulated AVP release from both the hypothalamus as well as the amygdala, in a dose-dependent manner with a maximum response at a concentration of 100 U/ml. For the hypothalamus, there was a slight, but statistically significant, increase observed with IL-2 at 1 U/ml. In contrast to the hypothalamus, IL-2 at 1 or 10 U/ml did not significantly increase AVP release from the amygdala as compared to basal levels. There was an enormous increase in AVP release from both brain regions observed at IL-2 concentration of 50 and 100 U/ml (for the hypothalamus, 235 + 21% and 389 f 32%, and for the amygdala, 257 f 30% and 440 ? 40% over basal, respectively).
Effect of sodium nitroprusside on the basal A VP release To determine whether nitric oxide might be involved in AVP release, hypothalamic and amygdala slices were incubated in the presence of 100 PM sodium nitroprusside, which generates NO. As shown in Figure 2, A IL-2 (U/ml) Figure 1 . Effect of IL-2 on the basal AVP release from the hypothalamus (A) and amygdala (B). After an 80 min preincubation, a baseline sample was collected for a period of 20 min. The basal values given are the average of the periods collected before the IL-2 stimulation. Incubation was carried out with medium containing increasing concentrations IG2 (1, 10,50, and 100 U/ml) in the subsequent period (between 100 and 120 min). In all the subsequent experiments, during the last 20 mm, incubation was carried out in 60 mM KC1 to test the viability of the slices (data not shown). All values given are means + SEM. n = 7-11 for hypothalamus (A); n = 5-14 for amygdala (B). *, p < 0.05 versus basal, 0, p < 0.01 versus basal. increased the AVP release from both the hypothalamus and amygdala, respectively.
Efect of LNMA and cobalt chloride on the IL-2-induced AVP release
To determine whether IL-2 induces the AVP release via NO, the IL-2-induced AVP release was assessed in the presence of 10 PM LNMA, an inhibitor of NOS. LNMA did not alter the basal AVP release from either the hypothalamus or amygdala (Fig. 3A,B) . However, LNMA completely blocked the IL-2 (100 U/ml)-induced AVP release from both brain regions. To study whether the IL-2-induced AVP release is calcium dependent, Between 80 and 120 min, incubation was carried out in the presence or absence of LNMA (10 FM) or cobalt chloride (10 mM). IL-2 (100 U/ml) was present between 100 and 120 min. All values given are means f SEM. n = 7-19 for hypothalamus (A); n = 14-28 for amygdala (B). *, p < 0.01 versus basal.
hypothalamic and amygdala slices were stimulated by IL-2 (100 U/ml) in the presence of 10 mM CoCl,, a nonspecific blocker of calcium channels (Cooper et al., 1991) . In the presence of CoCl,, the effects of IL-2 were completely antagonized; IL-2 no longer stimulated AVP release (Fig. 3AJ ).
Efect of LNMA and DNMA on the acetylcholine-induced AVP release
Next we examined the role of NO in the AVP released by other neurotransmitters, such as acetylcholine and norepinephrine. Acetylcholine is known to evoke a significant increase in AVP release from the hypothalamus and the amygdala (Raber et al., 1994) . To determine the role of NO in the acetylcholine-induced Between 80 and 120 min, incubation was carried out in the absence or presence of LNMA or DNMA (10 PM). Acetylcholine (1 FM) was present during the subsequent period (between 100 and 120 min). All values given are means + SEM. n = 7-13 for hypothalamus (A); n = 9-10 for amygdala (B). *, p < 0.01 versus basal; 0, p < 0.05 versus basal.
AVP release, the 1 PM acetylcholine-induced AVP release in the presence of 10 PM LNMA was examined (Fig. 4A,B) . LNMA completely blocked the acetylcholine-induced AVP release from the hypothalamus and amygdala. In order to ascertain that the inhibition of the acetylcholine-induced AVP release is specific, the acetylcholine-induced AVP release was assessed in the presence of 10 PM DNMA, the inactive analog of LNMA. DNMA did not significantly alter the acetylcholine-induced AVP release in both brain regions.
Efect of phentolamine and propanolol on the norepinephrine-induced A VP release Norepinephrine (1 PM) strongly induced the release of AVP not only from the hypothalamus but also from the amygdala (Fig.   5A,B) . To investigate the adrenergic receptor(s) involved in the AVP release from these brain regions, the norepinephrine-induced AVP release in the presence of phentolamine or propan-0101 was assessed. Propanolol(l0 PM) did not significantly alter the norepinephrine-induced AVP release from either the hypothalamus or the amygdala. However, phentolamine (10 PM completely blocked the norepinephrine-induced AVP release from these areas.
Efect of LNMA on the norepinephrine-induced AVP release
To study if NO mediated signaling is involved in the norepinephrine-induced AVP release from the hypothalamus or amygdala, the norepinephrine-evoked release was assessed in the presence of LNMA. As shown in Figure 6 , A and B, LNMA (10 PM) did not significantly alter the norepinephrine-induced AVP release from the hypothalamus or the amygdala.
Discussion
Our results provide evidence for a rapid calcium-and dosedependent release of AVP by IL-2, not only from the rat hy-Raber and Bloom * IL-2 Potentiation of Vasopressin Rel ease pothalamus, but also from the amygdala in vitro. In addition, sodium nitroprusside, a generator of NO, also induces AVP release. Further, our findings demonstrate that while the IL-2-and acetylcholine-induced AVP release may be mediated via production of NO, the AVP release induced by norepinephrine is not. The norepinephrine-induced AVP release is antagonized by phentolamine but not by propanolol, suggesting an cu-adrenergic receptor-mediated AVP response in both the hypothalamus and the amygdala.
The IL-2-induced release of AVP from the amygdala also raises the possible involvement of the amygdala in neuroimmune interactions. This is in agreement with the proposed role for the amygdala in the immune response, based on measurements of the cellular immune response as well as DNA synthesis after small electrolytic lesions (Masek et al., 1992) . They suggest three possible immune-regulatory neurocircuits: (1) the catecholaminergic cell groups A,-A, in reticular formation, nucleus parabrachialis, and central nucleus of the amygdala; (2) the serotonergic raphe groups B, and B,, the hypothalamus, and the basomedial nucleus of the amygdala; (3) the basomedial and central nuclei of the amygdala and the medial frontal cingulate cortex areas 1 and 2.
The present findings that nitroprusside induces AVP release and that the IL-a-/and acetylcholine-induced AVP release is blocked by LNMA from the hypothalamus as well the amygdala, strongly suggest that NO can mediate AVP release. These findings are in agreement with the recently reported dose-dependent increase in plasma AVP after intracerebroventricular injection in rats of S-nitroso-N-acetylpenicillamine (SNAP), which spontaneously breaks down to form NO, or L-arginine, the precursor for NO synthesis (Ota et al., 1993) ; these effects might explain the inhibition of water diuresis after intracerebroventricular injection of L-arginine in hydrated goats (Eriksson et al., 1982) .
Nitroprusside (100 KM) produced only moderate, but significant, increases in AVP release from both the hypothalamus and amygdala ( Fig. 2A,B) . This is in line with the relatively large doses of SNAP and of L-arginine required to produce moderate increases in plasma AVP (Ota et al., 1993) and the relatively small induction of prostaglandin E, (PGE,) by nitroprusside (100 WM) from the hypothalamus in vitro (Rettori et al., 1992) . The reason for this effect is not yet clear.
Two main classes of NOS can be distinguished, a calciumindependent calmodulin-containing endotoxin and/or cytokineinducible form of the enzyme and a calcium-dependent constitutive form (for review, see Henry et al., 1993) . The blocking of the IL-2-induced AVP release from both the hypothalamus and the amygdala by cobalt chloride (Fig. 3AJ ) may indicate the involvement of the constitutive form of NOS or the inability of the activated enzyme to release AVP in the absence ofcalcium and a potential direct effect of CoCl, on AVP release from secretory granules. However, the observed effects induced by IL-2, acetylcholine, and nitroprusside occurred within 20 min, while the cytokine induction of NOS shows a several hour delay (Kilbourn and Belloni, 1990; Moncada et al., 1991; Simmons and Murphy, 1993) . These time differences support the involvement of the constitutive enzyme. The basal AVP release from both the hypothalamus, as well as the amygdala, is unaffected by NMLA or cobalt chloride (Fig. 3A,B) . This indicates that NO is unlikely to mediate basal AVP release.
The present findings that IL-2-and acetylcholine-induced AVP release are mediated via production of NO, but not that induced by norepinephrine, are similar to in vitro data for CRF. In that case IL-2 stimulated hypothalamic CRF release in some hands (Calogero et al., 1987; Cambronero et al., 1992) , but not others (Buzetti et al., 1988; Navarra et al., 1991) . In addition NO signaling has been implicated in the IL-2 or cholinergic induction of hypothalamic CRF release, but not that induced by norepinephrine (Karanth et al., 1993) . Our observation that AVP was clearly released from the hypothalamus by IL-2 suggests that in addition to CRF, AVP may also mediate the IL-2 stimulation of ACTH secretion (Bindon et al., 1983; Lotze et al., 1985; Atkins et al., 1986; Denicoff et al., 1989) .
The mechanism for the IL-2 modulation of AVP release is still to be determined. It is unlikely that IL-2, at our doses tested (l-100 U/ml), interacted with acetylcholine to cause the AVP release. IL-2 does not change the basal acetylcholine release and decreases the potassium-evoked acetylcholine release from either hippocampal or frontal cortical slices (Araujo et al., 1989; Hanisch et al., 1993) ; IL-2 only increases the evoked release of acetylcholine in the hippocampus at very low concentrations (1.5 mu/ml) (Hanisch et al., 1993) .
The nature of the IL-2 receptor signal transduction also remains unclear. The IL-2 receptor components (a, p, and y) lack an intrinsic protein kinase domain, common to other growth factor receptors, and may utilize Src family tyrosine kinases and/or ~21'~ for the induced phosphorylation of cellular proteins (for review, see Taniguchi and Minami, 1993) . Hypothetically, the activated IL-2 receptor could phosphorylate cholinergic receptors and in this way induce AVP release. For purified rat brain muscarinic receptors, carbachol-induced phosphorylation has been reported, and their phosphorylation states correlate with translocation and recycling of these receptors between plasma membrane and cytosol (Ho et al., 1990) . However, the biological function of this phosphorylation is not yet clear. Some reports suggest that IL-2 stimulates T-cell proliferation by decreasing CAMP production and PKC activation (Farrar and Anderson, 1985; Evans et al., 1987; Altman et al., 1992) . Interestingly, PKC activation increased the electrically evoked neurohypophysial AVP release in vitro, while PKC inhibition reduced it (Racke et al., 1989) raising an alternative possibility for the mechanism of IL-2-induced AVP release.
For some analogs of L-arginine, direct effects on muscarinic receptors have been reported (Buxton et al., 1993) . The fact that Ne-nitro+arginine (L-NAME), but not LNMA, seems to be a competitive muscarinic receptor antagonist indicates that the observed inhibition of the acetylcholine-induced AVP release occurs by blocking NO production. NO was reported to be involved in the induction of cGMP production by muscarinic receptors in rat primary cortical cultures, containing glial and neuronal elements (Castoldi et al., 1993) . Thus, blocking NO synthesis may prevent muscat-uric signal transduction. This could explain the inhibition of acetylcholine-induced AVP release in the presence of LNMA (Fig. 4A,B) , since a blockade of the muscarinic receptor alone is sufficient to antagonize completely the acetylcholine-induced AVP release in the hypothalamus and amygdala (Raber et al., 1994) .
The potent effect of IL-2 on the release of AVP could be due to a direct effect on AVP neurons or via an effect on astrocytes and/or microglia. The recently reported dose-dependent induction by purified rat IL-2 of L-argininedependent cGMP levels and protein synthesis in astrocytes (Simmons and Murphy, 1993) and the presence of AVP receptors on these cells (Hosli et al., 1992) raise the possibility of astrocytic involvement in the interaction between IL-2 and AVP.
The noradrenergic system controlling hypothalamic AVP release is localized mainly in the PVN and SON, and to a small extent in the dorsomedial nucleus (Leibowitz et al., 1990) . The PVN and SON are innervated by noradrenergic fibers from the A,-and A,-catecholaminergic cells of the brainstem and from the locus coeruleus (McNeil and Sladek, 1980; Sawchenko and Swanson, 1982) and the presence of ~yl, 0~2, and p adrenergic receptors in the PVN and SON have been reported (Leibowitz et al., 1982; Unnerstall et al., 1984) . In the present study, we demonstrate that the norepinephrine-induced AVP release is antagonized by phentolamine but not by propanolol, suggesting an Lu-adrenergic receptor-mediated AVP response in both the hypothalamus, as well as the amygdala. These results are in agreement with other reports showing a norepinephrine-mediated stimulatory effect on the hypothalamic AVP release (Benetos et al., 1986; Leibowitz et al., 1990; Renaud and Bourque, 1991) , which is mediated by (Y adrenoceptors (Hillhouse and Milton, 1989; Veltmar et al., 1992) .
Norepinephrine can also induce AVP release from the amygdala. Among the AVP-containing neurons identified in the amygdala (De Vries et al., 1985) , the central amygdaloid nucleus may be a possible site of interaction between norepinephrine and AVP, like described for its interaction with CRF (Ray et al., 1993) , since in the late phase of hypertension there is an increased release of norepinephrine detected, using push-pull techniques (Diet& 1987) . The amygdaloid complex is involved in stress-related reactions (Singh et al., 1990) and in the regulation of the hypothalamo-pituitary-adrenal (HPA) axis (Dunn and Whitener, 1986) . The involvement and requirement for central catecholamines in the HPA response to exogenous cytokines (Weidenfeld et al., 1989) or stress (Gaillet et al., 199 l) , for adrenergic receptors in the PVN in the angiotensin II-induced AVP release (Veltmar et al., 1992) , and the nicotineinduced neuronal activation in brainstem catecholaminergic regions and their projection fields in parvocellular PVN and SON (Matta, 1993) , suggest a significant role in regulating AVP release.
In summary, we have found that IL-2 can modulate the AVP release from the hypothalamus and amygdala in vitro, suggesting a role for not only the hypothalamus, but also the amygdala in neuroimmune interactions. In addition, NO was found to be involved in the IL-2-and acetylcholine-induced AVP release from both brain regions, but not in the one induced by (Y-adrenoceptor stimulation. The exact mechanism by which IL-2 modulates AVP release remains to be determined, and could clarify pathophysiologic or toxic effects of high brain levels of IL-2.
